WATERTOWN, Mass., September 29, 2026--ai3Bio launches with $48M in Series A funding to reset the immune system at its root, advancing platforms targeting Th17 cells in vivo.
Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33, a clinical-stage ...
Researchers at Washington University School of Medicine in St. Louis have developed a potential antibody-based approach to ...
Cell surface protein labeling supports precise characterization of immune checkpoints, receptors, and other therapeutic ...
Lund University. For most of his career as a researcher, Lars Björck has sought to understand how bacteria manage to evade ...
The EADV Congress 2026 will take place September 30 - October 3, 2026 in Vienna, Austria and FCD 2026 will take place on October 8-11, 2026 in Las Vegas, Nevada. Presentation details are below. Title: ...
The first clinical programme from Currus’ BEAT platform, designed to overcome the barriers that have limited CAR T-cell therapy in solid tumoursCUR-001 combines CURB-001, Currus’ BEAT bispecific ...
Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the signing of an exclusive distribution agreement ...
Welltica+ on MSN
New vaccine aims to block the high from powerful opioids
American researchers are working on a new method that could reduce the effects of powerful opioids such as fentanyl and ...
All NDV field strains belong to a single serotype (APMV-1), so therefore standard vaccines (e.g. LaSota, B1) still can neutralize Genotype VII NDV: a change in genotype does not mean a change in ...
AstraZeneca shares hit a two-month high after a $2bn Summit Therapeutics deal. We look at what ivonescimab means for AstraZeneca's oncology pipeline and the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results